Cenix will initially focus on finding and validating oncology targets as well as developing a related RNAi dataset.

Cenix BioScience will help AstraZeneca advance discovery activities and validate drug targets. Cenix will combine high-throughput (HT) applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells.


The initial project will involve an HT-RNAi screen using an assay strategy codesigned with AstraZeneca to discover and validate oncology targets. Cenix will use Definiens’ Cellenger image-analysis platform to implement multiparametric microscopy-based assays. The company reports that this will lead to insights into cellular functions and loss-of-function phenotypes of analyzed genes.


Cenix hopes to expand the collaboration beyond oncology into multiple projects, says Christophe Echeverri, CEO and CSO.

Previous articleScientists Create Computational Technique for Finding Disease-Associated Genetic Regions
Next articleAlkermes Prompted to Restructure with Eli Lilly’s Decision to Drop Inhaled Insulin Development